Lornoxicam (CAS 70374-39-9) Product Details
Lornoxicam, with CAS Number 70374-39-9, is a potent non-steroidal anti-inflammatory (NSAID) belonging to the oxicam class, also known as Chlortenoxicam or Ro 13-9297. It exhibits strong analgesic, anti-inflammatory and antipyretic properties, and is widely used in global medical practice, clinical trials and pharmaceutical R&D. As a high-purity pharmaceutical raw material, it strictly complies with international standards (GMP, USP, EP) and meets the regulatory requirements of major global markets, suitable for the production of oral and injectable dosage forms as well as scientific research applications.
Product Basic Information
|
Item
|
Details
|
|
CAS Number
|
70374-39-9
|
|
Product Name
|
Lornoxicam; Chlortenoxicam; Ro 13-9297; Xefo® (marketed brand)
|
|
Chemical Formula
|
C₁₃H₁₀ClN₃O₄S₂
|
|
Molecular Weight
|
Approx. 371.82
|
|
Appearance
|
Faint Yellow to Dark Yellow Solid Powder
|
|
Purity
|
≥98% (HPLC); ≥99% available for medical grade; Single impurity ≤1%
|
|
Solubility
|
DMSO: >5 mg/mL (warmed for better solubility); Slightly soluble in methanol and water; Insoluble in non-polar solvents
|
|
Storage Condition
|
Sealed, Protected from Light and Inert Atmosphere; Stored at -20°C for long-term storage (2 years); 2-8°C for short-term storage (6 months); Avoid moisture and extreme temperature changes
|
|
Shelf Life
|
24 Months under Proper Storage Conditions (powder)
|
|
Key Identifiers
|
EINECS: 630-354-7; MDL Number: MFCD00866163; ATC Code: M01AC05
|
Pharmacological Action & Clinical Applications
Mechanism of Action
Lornoxicam exerts its analgesic, anti-inflammatory and antipyretic effects mainly by inhibiting the activity of cyclooxygenase (COX), including both COX-1 and COX-2 isoenzymes. It potently blocks the biosynthesis of prostaglandins and thromboxanes from arachidonic acid, thereby reducing inflammation, , fever and swelling. Unlike some other NSAIDs, it does not inhibit 5-lipoxygenase activity, so it does not affect leukotriene synthesis or divert arachidonic acid to the 5-lipoxygenase pathway. Additionally, it activates the opioid neuropeptide system to exert a central analgesic effect, enhancing its -relieving efficacy. It has an IC50 of 3 nm for inhibiting thromboxane B2 (TXB2) synthesis in human erythroleukemic cells and 8 nm for inhibiting LPS-induced prostaglandin F1α (PGF1α) formation in mono-mac-6 cells.
Main Clinical Uses
-
Management: Used for the treatment of acute mild to moderate , including postoperative , associated with acute low back and sciatica, as well as from joint inflammatory diseases.
-
Inflammatory Diseases: Applied in the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and other rheumatic diseases to relieve inflammation and symptoms.
-
Pharmaceutical R&D: Serves as a key raw material for the production of oral and injectable dosage forms, and as a tool compound for researching COX inhibitors and new anti-inflammatory s.
-
Preclinical Research: Used in animal experiments (such as rat carrageenan-induced paw edema models) to evaluate anti-inflammatory and analgesic efficacy, providing a basis for clinical application research.
Contraindications & Adverse Reactions
Contraindications: Prohibited for patients with hypersensitivity to any component of the product; patients who have induced asthma, urticaria or allergic reactions after taking aspirin or other NSAIDs; patients undergoing perioperative treatment for coronary artery bypass grafting (CABG); patients with a history of gastrointestinal bleeding or perforation caused by NSAIDs; patients with active peptic ulcer/bleeding or a history of recurrent ulcer/bleeding; patients with severe heart failure, coagulation disorders, moderate to severe renal impairment, severe liver impairment, cerebral hemorrhage or suspected cerebral hemorrhage; pregnant and lactating women; and patients under 18 years old or over 65 years old with insufficient clinical experience.
Adverse Reactions: Common reactions include injection site-related symptoms (, redness, tingling, tension), stomach , nausea, vomiting, dizziness, drowsiness, headache and skin flushing. Rare reactions include flatulence, restlessness, indigestion, diarrhea, increased blood pressure, palpitations, chills, excessive sweating, taste disorders, dry mouth, leukopenia, thrombocytopenia and dysuria. Long-term use may increase the risk of cardiovascular thrombotic adverse events, myocardial infarction and stroke, as well as severe skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Export Compliance & Trade Information
Regulatory Attribute
Lornoxicam is classified as a pharmaceutical raw material (NSAID) in China, subject to the administration of Import and Export License (Regulatory Code: L). It complies with GMP, USP, EP and other international pharmaceutical standards, and meets the regulatory requirements of major global markets such as the EU, the United States, Japan and Southeast Asia. It is a prescription in most countries and regions, not a controlled substance, but requires strict compliance with local pharmaceutical regulations.
HS Code & Declaration Elements
Recommended HS Code: 2934999090 (Other heterocyclic compounds; subject to the latest customs code of the importing country); For finished dosage forms, refer to HS Code 3004 (Medicaments for therapeutic or prophylactic uses). Note that ECCN (Export Control Classification Number) should be confirmed based on local regulations for US exports.
Declaration Elements: CAS Number, Product Name, Purity, Usage (Medical/Pharmaceutical R&D), Composition, Brand, Chemical Formula, ATC Code (if applicable), etc.
Export Documentation Requirements
-
Export Sales Certificate (valid for 3 years), issued by the provincial regulatory authority of China.
-
Import License or official certification of the importing country (if required), especially complying with FDA regulations for the US market and EMA requirements for the EU market (including CEP certification if applicable).
-
Relevant qualifications: GMP Certificate, Production Approval Number, Sales Contract, Certificate of Origin, etc.
-
Test Reports: COA (Certificate of Analysis), MSDS (Material Safety Data Sheet), purity test report (HPLC), melting point test report, and heavy metal test report (≤10ppm, available upon request).
Logistics & Packaging
Packaging: Aluminum foil bag or glass vial, labeled with "Pharmaceutical Raw Material, Protect from Light, Keep Dry, Inert Atmosphere", chemical formula and storage conditions; sealed packaging to prevent moisture, contamination and degradation. Vacuum-packed options are available upon request. Labeling should comply with GHS classification requirements (Signal Word: Danger; Hazard Statement: H300) and local pharmaceutical packaging regulations.
Transportation: Ambient temperature shipping is acceptable for short-distance transportation (stable at room temperature for several days during shipping and customs clearance); cold chain transportation (shipping with blue ice) is recommended for long-distance or high-temperature environments to ensure product quality. Avoid extreme temperature changes, moisture and direct sunlight.
Quality Assurance & After-Sales Service
-
Strict Quality Control: Each batch of products undergoes HPLC, MS and melting point verification tests to ensure purity, stability and chemical structure accuracy; heavy metal, residue and microbial tests are available upon request. Product quality meets USP, EP and CP standards.
-
Customized Service: We can provide customized packaging and specifications according to customer needs, including small-volume research-grade products (≥98% purity) and large-volume pharmaceutical-grade products (≥99% purity), as well as customized technical support for dosage form development.
-
After-Sales Support: Provide professional technical guidance (including solubility and formulation guidance), timely solve logistics and customs clearance problems, and ensure smooth trade; provide relevant regulatory compliance guidance for specific markets (such as EU CEP certification guidance).
